Empagliflozin Efficacy and Safety in Type 2 Diabetes

Efficacy and Positioning in Treatment Algorithm

• In patients with type 2 diabetes, empagliflozin reduces A1C by 0.84% compared to placebo, as observed in youth aged 10-17 years 1
• The American Diabetes Association recommends metformin as first-line therapy for most patients with type 2 diabetes, with each new class of non-insulin agent added to metformin generally lowering A1C by approximately 0.7-1.0% 2
• For patients with established cardiovascular disease or high CV risk, empagliflozin is recommended as part of the glucose-lowering regimen independent of A1C level, according to the American College of Cardiology 3, 4

Cardiovascular Benefits and Renal Function

• Empagliflozin has demonstrated cardiovascular benefits beyond glycemic control, reducing cardiovascular death and hospitalization for heart failure in patients with established ASCVD, as recommended by the American College of Cardiology 3, 4
• The American College of Cardiology recommends against using empagliflozin for glycemic control when eGFR <45 mL/min/1.73 m², due to decreased efficacy in patients with renal impairment 5

Safety Considerations and Dosing

• The risk of hypoglycemia increases when empagliflozin is combined with insulin or sulfonylureas, but no severe hypoglycemia occurred in the pediatric trial, as reported in Diabetes Care 1
• The American College of Cardiology recommends starting with empagliflozin 10 mg once daily, with no dose titration beyond 10 mg necessary for cardiovascular risk reduction 4
• The maximum approved daily dose is 25 mg, as stated in Diabetes Care 3

A1C Reduction with Empagliflozin

Efficacy and Durability

• The American Diabetes Association acknowledges that empagliflozin produces a moderate glucose-lowering effect, particularly when compared to GLP-1 receptor agonists, with sustained efficacy over 76 weeks of treatment 6
• The glucose-lowering effect of empagliflozin is considered moderate, and patients with higher baseline A1C values may require more aggressive combination therapy from the outset, as the A1C reduction is less than additive compared to monotherapy effects 6

Clinical Positioning and Combination Therapy

• The American Heart Association recognizes that while empagliflozin has proven cardiovascular and renal benefits, its glucose-lowering potency is moderate, and GLP-1 receptor agonists are positioned above SGLT2 inhibitors in treatment hierarchies due to greater glycemic potency 6
• Many patients will require combination therapy with GLP-1 receptor agonists, SGLT2 inhibitors, and metformin to achieve glycemic goals, as stated by the American Association of Clinical Endocrinologists 6

Empagliflozin Efficacy and Safety in Type 2 Diabetes

Introduction to Empagliflozin

• The American College of Cardiology recommends empagliflozin as a treatment option for patients with type 2 diabetes, with A1C reduction of approximately 0.5% to 0.8% depending on baseline glycemic control and renal function 7

Expected A1C Reduction by Clinical Context

• The Chinese Diabetes Guidelines report SGLT2 inhibitors, such as empagliflozin, reduce A1C by approximately 0.5% to 1.0% 7

Impact of Renal Function on Efficacy

• The American College of Cardiology states that the glucose-lowering effect of empagliflozin decreases substantially with declining renal function, with A1C reduction of -0.6% for eGFR 60 to <90 mL/min/1.73 m², -0.5% for eGFR 45 to <60 mL/min/1.73 m², and -0.2% for eGFR 30 to <45 mL/min/1.73 m² 8
• The American College of Cardiology advises against using empagliflozin for glycemic control when eGFR <45 mL/min/1.73 m², but recommends its use for cardiovascular and renal protection down to eGFR ≥25 mL/min/1.73 m² in patients with established cardiovascular disease or diabetic nephropathy with albuminuria 8, 9

Dose Comparison and Clinical Positioning

• The American College of Cardiology recommends a starting dose of 10 mg for cardiovascular risk reduction, with no dose titration beyond 10 mg necessary for this indication 9
• The American College of Cardiology notes that GLP-1 receptor agonists are positioned above SGLT2 inhibitors in treatment hierarchies due to greater glycemic potency, and many patients may require combination therapy with both a GLP-1 receptor agonist and SGLT2 inhibitor plus metformin to achieve glycemic goals 10

Important Caveats and Cardiovascular Benefits

• The American College of Cardiology advises reducing the insulin dose by approximately 20% or weaning/stopping the sulfonylurea when adding empagliflozin to patients already on insulin or sulfonylureas to prevent hypoglycemia 9
• The American College of Cardiology states that the cardiovascular and renal benefits of empagliflozin are independent of its glucose-lowering effect, and recommends its use in patients with type 2 diabetes and established cardiovascular disease regardless of baseline A1C level 11

Empagliflozin (Jardiance) Dose Escalation to 25 mg

Evidence Supporting Dose Increase

• In a pediatric trial of youth with type 2 diabetes, participants who had not reached an A1C < 7 % after 12 weeks were randomized to continue 10 mg or to increase to 25 mg; the trial demonstrated that escalation to 25 mg is an evidence‑based strategy for achieving glycemic targets. 12

• The 2025 American Diabetes Association guidelines cite the same youth trial, confirming that dose escalation to 25 mg is recommended when A1C goals are not met on the 10 mg dose. 12

Glycemic Efficacy of the 25 mg Dose

• When data from the 10 mg and 25 mg empagliflozin arms were pooled and compared with placebo, the combined treatment produced an average A1C reduction of 0.84 % (P = 0.012) without any episodes of severe hypoglycemia. 12

Safety Profile Relevant to Dose Escalation

• Across the pediatric trial, empagliflozin (both 10 mg and 25 mg) was associated with minimal risk of hypoglycemia; no severe hypoglycemic events occurred during the study period. 12